de Andrade Gandolfi F, Estofolete C, Wakai M, Negri A, Barcelos M, Vasilakis N
Vaccines (Basel). 2023; 11(2).
PMID: 36851322
PMC: 9962731.
DOI: 10.3390/vaccines11020445.
Abreu A, Cavalcante J, Wigg de Araujo Lagos L, Caetano R, Braga J
Vaccines (Basel). 2022; 10(5).
PMID: 35632466
PMC: 9147422.
DOI: 10.3390/vaccines10050711.
Ruggieri A, Helm M, Chatel-Chaix L
RNA Biol. 2020; 18(5):696-708.
PMID: 33356825
PMC: 8078509.
DOI: 10.1080/15476286.2020.1868150.
Lecomte E, Laureys G, Verbeke F, Domingo Carrasco C, Van Esbroeck M, Huits R
J Travel Med. 2020; 27(7).
PMID: 32965473
PMC: 7649383.
DOI: 10.1093/jtm/taaa172.
Goldstein E, Bell D, Gunson R
BMJ Case Rep. 2019; 12(5).
PMID: 31088820
PMC: 6536176.
DOI: 10.1136/bcr-2019-229558.
Visualization of a neurotropic flavivirus infection in mouse reveals unique viscerotropism controlled by host type I interferon signaling.
Li X, Li X, Deng C, Dong H, Zhang Q, Ye Q
Theranostics. 2017; 7(4):912-925.
PMID: 28382163
PMC: 5381253.
DOI: 10.7150/thno.16615.
Yellow fever vaccine-associated viscerotropic disease: current perspectives.
Thomas R
Drug Des Devel Ther. 2016; 10:3345-3353.
PMID: 27784992
PMC: 5066857.
DOI: 10.2147/DDDT.S99600.
Spectrum of disease outcomes in mice infected with YFV-17D.
Erickson A, Pfeiffer J
J Gen Virol. 2015; 96(Pt 6):1328-1339.
PMID: 25646269
PMC: 4635484.
DOI: 10.1099/vir.0.000075.
Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner.
Oreja-Guevara C, Wiendl H, Kieseier B, Airas L
Ther Adv Neurol Disord. 2014; 7(2):137-49.
PMID: 24587828
PMC: 3932767.
DOI: 10.1177/1756285613501575.
A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.
Edupuganti S, Eidex R, Keyserling H, Akondy R, Lanciotti R, Orenstein W
Am J Trop Med Hyg. 2012; 88(1):172-7.
PMID: 23208880
PMC: 3541731.
DOI: 10.4269/ajtmh.2012.12-0179.
Methodology for definition of yellow fever priority areas, based on environmental variables and multiple correspondence analyses.
Moreno E, Barata R
PLoS Negl Trop Dis. 2012; 6(7):e1658.
PMID: 22802971
PMC: 3389021.
DOI: 10.1371/journal.pntd.0001658.
Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
Gershman M, Staples J, Bentsi-Enchill A, Breugelmans J, Brito G, Camacho L
Vaccine. 2012; 30(33):5038-58.
PMID: 22561144
PMC: 3425393.
DOI: 10.1016/j.vaccine.2012.04.067.
Yellow fever: a reemerging threat.
Gardner C, Ryman K
Clin Lab Med. 2010; 30(1):237-60.
PMID: 20513550
PMC: 4349381.
DOI: 10.1016/j.cll.2010.01.001.
A case of yellow fever vaccine-associated viscerotropic disease in Ecuador.
Douce R, Freire D, Tello B, Vasquez G
Am J Trop Med Hyg. 2010; 82(4):740-2.
PMID: 20348528
PMC: 2844553.
DOI: 10.4269/ajtmh.2010.09-0570.
[Vaccination and multiple sclerosis].
Lobermann M, Winkelmann A, Reisinger E, Zettl U
Nervenarzt. 2009; 81(2):181-93.
PMID: 19838662
DOI: 10.1007/s00115-009-2865-3.
Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
Julander J, Shafer K, Smee D, Morrey J, Furuta Y
Antimicrob Agents Chemother. 2008; 53(1):202-9.
PMID: 18955536
PMC: 2612161.
DOI: 10.1128/AAC.01074-08.
Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?.
Martins M, Silva M, Marciano A, Peruhype-Magalhaes V, Eloi-Santos S, Ribeiro J
Clin Exp Immunol. 2007; 148(1):90-100.
PMID: 17309541
PMC: 1868854.
DOI: 10.1111/j.1365-2249.2006.03317.x.
Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model.
Julander J, Morrey J, Blatt L, Shafer K, Sidwell R
Antiviral Res. 2006; 73(2):140-6.
PMID: 17049380
PMC: 1828627.
DOI: 10.1016/j.antiviral.2006.08.008.
Deadly viral syndrome mimics.
Lowenstein R
Emerg Med Clin North Am. 2004; 22(4):1051-65, ix-x.
PMID: 15474781
PMC: 7135824.
DOI: 10.1016/j.emc.2004.05.005.
A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
Guirakhoo F, Zhang Z, Myers G, Johnson B, Pugachev K, Nichols R
J Virol. 2004; 78(18):9998-10008.
PMID: 15331733
PMC: 514991.
DOI: 10.1128/JVI.78.18.9998-10008.2004.